Patrick Wolfe

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada.

Microbion Corp. develops topical microbial therapeutic products. It safeguards human health by overcoming infections, antibiotic resistance, and microbial biofilms with safe, effective anti-infective products. The firm is developing MBN-101 as the first product in a new class for the treatment of antibiotic-resistant and difficult to treat infections. The company was founded by Brett H. Baker and is headquartered in Bozeman, MT.

Alafair Biosciences, Inc. operates as a medical device company. It develops novel suite of products based on a non-cell adhesive hydrogel technology that protects and manages advanced wound healing. The firm addresses problems of wound healing and scar prevention with natural, animal-free biopolymer based products that are biocompatible, bioresorbable and hydrate injured tissues throughout healing. The company was founded by Daniel L. Peterson, John D. Joyoprayitno and Sarah Mayes in 2011 and is headquartered in Austin, TX.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Ellipsis Neurotherapeutics, Inc. develops pharmaceutical products for treatment and preventing of Alzheimer's disease and related disorders. The firm commercializes neurodegenerative disease therapeutics and diagnostics. The company was founded by Laurence Rubin in November 2004 and is headquartered in Toronto, Canada.

Beth Israel Deaconess Medical Center provides medical services. It offers patient care, biomedical research, teaching, and community services. It also provides organ transplantation, breast cancer care, and cardiac surgery services. The company was founded in 1896 and is headquartered in Boston, MA.

Founded in 1923, Mount Sinai Hospital (Canada) operates a hospital. The company is based in Toronto, Canada.

BIOTECanada serves as a national association for Canada's health, industrial and agricultural biotechnology sectors. The company was founded in 1986 and is headquartered in Ottawa, Canada.

Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel.

Center for Drug Research & Development operates as a drug development and commercialization company. The firm provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. The company was founded in 2007 and is headquartered in Vancouver, Canada.

Bio-MarCare Technologies Ltd. develops diagnostic kits based on novel biomarkers for early cancer identification, monitoring and assistance. Its product mCRC-Strat is a personalized medicine assay predicting responsiveness to anti EGFR therapy and Colon-MarCarePlex is a molecular assay (qRT-PCR) comprising a panel of RNA markers that can detect the advanced adenoma polyps as well as early stage colorectal cancer. The company was founded by Beatrice Uziely and Rachel Bar-Shavit in 2002 and is headquartered in Jerusalem, Israel.

Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada.

Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada.

CDRD Ventures, Inc. engages in the development and production of therapeutic products. The company is headquartered in Vancouver, Canada.

Bedside Clinical Systems, Inc. develops Responses to Illness Severity Quantification (RISQ) framework severity of illness clinical decision support for frontline healthcare professionals, hospital administrators and quality managers. It provides BedsidePEWS, that uses the RISQ framework to empower frontline clinicians who care for hospitalized children. The company was founded by Christopher Parshuram in March 2011 and is headquartered in Toronto, Canada.

Treat U SA develops targeted nanotechnology-based platforms for the specific delivery of drugs in the oncology area. It offers PEGASEMP, a platform conceived for delivering a cytostatic agent specifically to the tumor microenvironment, targeting two distinct cell populations: the cancer cell and the endothelial cells from the tumor blood vessels. The firm operates through its offices in Cantanhede and Coimbra. The company was founded in January 2010 by Vera Moura and Sérgio Paulo de Magalhães Simões and is headquartered in Coimbra, Portugal.

Clinical Trials Ontario operates as a research and development company for various diseases. The company was founded in 2012 and is headquartered in Toronto, Canada.

Encycle Therapeutics, Inc. provides biotechnology services. It offers rapid synthesis of drug-like macrocycles or membrane-permeable nacellins which have enormous potential to target intracellular protein-protein interactions. The company was founded by Andrei Yudin is headquartered in Toronto, Canada.

Mercal Capital Corp. is a capital pool company, which engages in the identification and evaluation of potential acquisitions or businesses. The company was founded on August 31, 2015 and is headquartered in Ottawa, Canada.

Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX.

Triphase Accelerator Corp. develops oncology drug therapeutics. It engages in accelerating oncology products from pre-investigational new drug (pre-IND) to Phase I/Phase II POC. The firm?s product includes Marizomib which is used in cancer treatment. The company is headquartered in Toronto, Canada.

QD Solar, Inc. develops photovoltaic cells using colloidal quantum dot technology in Canada. Its quantum dot technology combines silicon solar cells with infrared solar cells in a hybrid architecture to harvest more of the solar spectrum than silicon alone. The company was founded by Sjoerd Hoogland and Edward Hartley Sargent in 2014 and is headquartered in Toronto, Canada.

Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety.

Telephus Medical LLC is a biotechnology company that develops immunotherapy products. The private company is based in Rochester, NY and was founded in 2012 by Mark Benedyk.

Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada.